Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the National Medical Products Administration (NMPA) to carry out a Phase I clinical study for its ABSK121, a fibroblast growth factor receptor (FGFR) drug resistance and mutation inhibitor, in advanced solid tumors. This marks a significant step forward in the development of innovative treatments for cancer.
ABSK121: Drug Profile and Efficacy
ABSK121, a second-generation small-molecule FGFR inhibitor, previously obtained clinical trial approval in the US. The drug not only showed the same anti-tumor efficacy as the currently approved FGFR inhibitor in many sensitive FGFR preclinical models but also demonstrated excellent efficacy in many FGFR-resistant mutant tumor models. This dual efficacy makes ABSK121 a promising candidate for addressing drug resistance in FGFR-driven cancers.
Abbisko’s FGFR Pipeline
Abbisko boasts a series of FGFR pipelines, including FGFR inhibitors ABSK091, ABSK011, and ABSK061, which target specific FGFR subtypes. The company also has new-generation FGFR inhibitors ABSK012 (for FGFR4 mutation) and ABSK121 (for FGFR1-3 mutation). These inhibitors represent Abbisko’s commitment to developing targeted therapies for various FGFR mutations.
Tumor Immunotherapy Portfolio
In addition to its FGFR inhibitors, Abbisko’s small-molecule tumor immunotherapies cover the main types of tumor microenvironment immune cells, including tumor-associated macrophages (TAMs), myelogenous suppressor cells (MDSC), Treg cells, Th17/Tc17 cells, and effector T cells. This comprehensive approach aims to modulate the tumor microenvironment and enhance the body’s immune response against cancer.
Strategic Implications
The NMPA’s approval for the Phase I clinical study of ABSK121 underscores Abbisko’s dedication to advancing innovative cancer therapies. By developing a robust pipeline of FGFR inhibitors and tumor immunotherapies, Abbisko aims to address significant unmet medical needs and improve patient outcomes. This initiative is expected to enhance Abbisko’s position in the global oncology market and contribute to the broader goal of advancing cancer treatment.-Fineline Info & Tech
